Abstract
The spleen plays a paramount role in the host protection against invading microrganisms. In support of the above concept, in splenectomized patients there is increasing evidence of overwhelming postsplenectomy infections (OPSI). OPSI are caused by Streptococcus pneumoniae in about 80% of cases, but also Gram-negative bacteria are implicated in a certain number of cases. Therapeutically, penicillin and pneumococcal vaccines represent valid therapeutic approaches in Gram-positive OPSI. However, the effectiveness of polyvalent polysaccharide pneumococcal vaccines is still debated and, thus, other therapeutic strategies should be validated for combating OPSI. According to our personal data, a deficit of phagocytic activities and of T helper (h)-1 cells is very frequent in splenectomized patients. In sera, we found reduced levels of both Interferon-γ and Interleukin (IL)-4. These data are in accordance with the recent observation on the protective role of T cells against S. pneumoniae. In fact, patients deficient in IL-12 develop severe pneumococcal infections and undergo apoptosis of Th1 cells.
Keywords: lymphocytes, macrophages, spleen, t helper cells, vaccines
Current Pharmaceutical Design
Title: The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications
Volume: 9 Issue: 24
Author(s): E. Jirillo, M. L. Mastronardi, M. Altamura, I. Munno, S. Miniello, G. Urgesi and L. Amati
Affiliation:
Keywords: lymphocytes, macrophages, spleen, t helper cells, vaccines
Abstract: The spleen plays a paramount role in the host protection against invading microrganisms. In support of the above concept, in splenectomized patients there is increasing evidence of overwhelming postsplenectomy infections (OPSI). OPSI are caused by Streptococcus pneumoniae in about 80% of cases, but also Gram-negative bacteria are implicated in a certain number of cases. Therapeutically, penicillin and pneumococcal vaccines represent valid therapeutic approaches in Gram-positive OPSI. However, the effectiveness of polyvalent polysaccharide pneumococcal vaccines is still debated and, thus, other therapeutic strategies should be validated for combating OPSI. According to our personal data, a deficit of phagocytic activities and of T helper (h)-1 cells is very frequent in splenectomized patients. In sera, we found reduced levels of both Interferon-γ and Interleukin (IL)-4. These data are in accordance with the recent observation on the protective role of T cells against S. pneumoniae. In fact, patients deficient in IL-12 develop severe pneumococcal infections and undergo apoptosis of Th1 cells.
Export Options
About this article
Cite this article as:
Jirillo E., Mastronardi L. M., Altamura M., Munno I., Miniello S., Urgesi G. and Amati L., The Immunocompromised Host: Immune Alterations in Splenectomized Patients and Clinical Implications, Current Pharmaceutical Design 2003; 9 (24) . https://dx.doi.org/10.2174/1381612033454306
DOI https://dx.doi.org/10.2174/1381612033454306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology Antibiotic Treatment in Native Valve Infective Endocarditis
Infectious Disorders - Drug Targets Metabolic Profiling in Multiple Sclerosis and Other Disorders by Quantitative Analysis of Cerebrospinal Fluid Using Nuclear Magnetic Resonance Spectroscopy
Current Pharmaceutical Biotechnology A Hyperlipidemic Diet Induces Structural Changes in Cerebral Blood Vessels
Current Neurovascular Research Monoclonal Antibodies in the Treatment of Leukemia
Current Molecular Medicine Current Status of Anti-Picornavirus Therapies
Current Pharmaceutical Design Pathophysiogenesis of Mesial Temporal Lobe Epilepsy: Is Prevention of Damage Antiepileptogenic?
Current Medicinal Chemistry The Role of Universal Stress Proteins in Bacterial Infections
Current Medicinal Chemistry Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination
Current Pharmaceutical Design Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Recent Patents Review on Intranasal Administration for CNS Drug Delivery
Recent Patents on Drug Delivery & Formulation Nasal Polyposis: An Overview of Differential Diagnosis and Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Inhibition of Virulence Factors and Biofilm Formation of <i>Acinetobacter Baumannii</i> by Naturally-derived and Synthetic Drugs
Current Drug Targets Enzyme Replacement Therapy for Lysosomal Storage Disorders
Recent Patents on Biomedical Engineering (Discontinued) Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Physiological Roles of Neurite Outgrowth Inhibitors in Myelinated Axons of the Central Nervous System – Implications for the Therapeutic Neutralization of Neurite Outgrowth Inhibitors
Current Pharmaceutical Design Management of Tuberculosis in Children and New Treatment Options
Infectious Disorders - Drug Targets Early Detection of Central Nervous System Relapse of Pediatric Leukemia with Measurement of Optic Nerve Sheath Diameter on MRI
Current Medical Imaging Tumour-Specific Uptake of Anti-Cancer Drugs: The Future is Here
Current Drug Metabolism